Dihydroberberine (DHB): Absorption, Dose and Evidence

Dihydroberberine (DHB) does get more berberine into your blood than regular berberine. In a small crossover study, 100 mg of DHB produced roughly 6 to 7 times more berberine in the blood over two hours than 500 mg of berberine. It has not yet been shown to give better blood sugar or cholesterol results in people. No published human trial has measured health outcomes for DHB over weeks or months, while regular berberine has dozens.

Evidence grade

• DHB raises blood berberine more than berberine. Grade: Limited. Why: Two tiny human studies (5 and 9 people), both industry linked.
• DHB improves blood sugar or cholesterol in people. Grade: Not shown. Why: No outcome trials; one pilot found no glucose difference.
• Regular berberine lowers glucose, lipids and waist size. Grade: Moderate. Why: Meta-analyses of many RCTs, mostly from China.
• DHB is safe. Grade: Limited. Why: Clean rat toxicology; little long term human data.

Key takeaways

• In Moon 2021 (5 young men, funded by DHB maker NNB Nutrition), 100 mg DHB gave a berberine blood exposure of 284 versus 42 ng/mL over 120 minutes for 500 mg berberine. Blood glucose and insulin after a meal did not differ.
• In animal studies, gut bacteria turn berberine into DHB, which crosses the gut wall and then converts back to berberine (Feng 2015).
• The trial benefits come from regular berberine, at 300 to 1,500 mg a day in a 2025 meta-analysis. A DHB dose that matches those effects has not been established.
• DHB has the same drug interaction concerns as berberine, and possibly stronger ones if blood levels are higher.

As an Amazon Associate, Stacking Years earns from qualifying purchases. This does not affect our rankings.

What dihydroberberine is

DHB is berberine with two extra hydrogen atoms. That small change makes it less water loving and easier to absorb through the gut wall. Once inside the body it converts back to berberine. So DHB is best thought of as a delivery form of berberine.

The idea is not new. In 2008, a team at Sydney's Garvan Institute (Turner, Diabetes) showed that berberine works partly by mildly slowing the cell's energy machinery (mitochondrial complex I), which activates the energy sensor AMPK. In the same paper, DHB countered weight gain, fat build up in tissues and insulin resistance in high fat fed rodents better than berberine, likely because more of it was absorbed.

Gut bacteria make DHB, at least in animals

Feng and colleagues (2015, Scientific Reports) found that gut bacteria convert berberine into DHB using enzymes called nitroreductases. In animals, DHB was absorbed about 5 times faster than berberine, then turned back into berberine in the gut wall before reaching the blood. When mice were given antibiotics to wipe out gut bacteria, less berberine reached the blood and berberine's glucose and lipid lowering effect weakened.

Two implications follow, if the same happens in people. Regular berberine would rely partly on gut bacteria to work, so results could vary between people. DHB skips that step, which could make it more consistent. That is a reasonable hypothesis, but it has not been tested in people.

The human studies

• Moon 2021, Nutrients. Who: 5 healthy young men, double blind crossover. Comparison: Placebo, berberine 500 mg, DHB 100 mg, DHB 200 mg (4 doses of each over about a day). Result: Berberine blood exposure over 120 min: 284 (DHB 100 mg) versus 42 (berberine 500 mg) ng/mL × min. No differences in glucose or insulin after a test meal. Funding: Funded by NNB Nutrition, maker of the DHB used (GlucoVantage).
• Chang 2024, Int J Mol Sci. Who: 9 healthy volunteers, pilot. Comparison: DHB versus a micellar berberine (LipoMicel). Result: DHB gave higher blood levels of berberine and most of its breakdown products; micellar berberine left more berberine unchanged. Funding: Most authors work at Isura, a nonprofit research group; one co-author owns Factors Group, whose Natural Factors brand supplied the micellar product.

Both studies measured how much berberine reached the blood over hours. Neither ran long enough to test blood sugar control, HbA1c, cholesterol or weight. A 2026 review of DHB research (Wang and Tang, Food and Chemical Toxicology) reached the same conclusion. The animal and cell data are strong, and human trials on actual health outcomes are still "highly limited."

What regular berberine has shown

For comparison, this is what the cheaper original form has behind it. A 2025 meta-analysis of 12 placebo controlled trials (Liu, Frontiers in Pharmacology), using 300 to 1,500 mg a day for 12 to 20 weeks, found these average changes.

• Fasting blood glucose. Average change versus placebo: Down 0.5 mmol/L (about 9 mg/dL).
• LDL cholesterol. Average change versus placebo: Down 0.5 mmol/L (about 19 mg/dL).
• Triglycerides. Average change versus placebo: Down 0.37 mmol/L.
• Waist size. Average change versus placebo: Down 3.3 cm.

It had no significant effect on HDL cholesterol or blood pressure, and side effects were no more common than with placebo. The US National Center for Complementary and Integrative Health (NCCIH) notes that a 2021 review of berberine for diabetes was mostly based on studies in Chinese patients and that some were of poor quality.

Our berberine guide covers that evidence in depth.

Should you choose DHB over berberine?

DHB may make sense if:

• Regular berberine upsets your stomach at the doses that work. Smaller DHB doses mean less material in the gut, though no trial has compared side effects directly.
• You want to try it knowing the evidence is about absorption, not outcomes.

Regular berberine HCl makes more sense if:

• You want the form with actual results in trials.
• You would rather not pay for a newer ingredient before outcome trials exist. Compare cost per day before switching.

Our berberine buying guide and product quality guide compare specific products and what to look for on a label.

Dose

There is no outcome based DHB dose. The Moon study used 100 mg and 200 mg doses with meals, and label directions vary between products. That study showed those doses beat 500 mg of berberine on blood levels over two hours, not that they match berberine's clinical effects.

Regular berberine trials in the Liu meta-analysis used 300 to 1,500 mg a day. NCCIH describes 200 to 1,000 mg two to three times daily as the range considered safe in clinical use.

Safety

• Toxicology. In lab and rat tests by consultants to Nanjing Nutrabuilding Bio-Tech, a Chinese ingredient company, DHB did not damage DNA, and 90 days at up to 100 mg per kg of body weight caused no observed harm in rats (Lewis 2022). The 2026 Wang review flags one open question, a possible effect on a heart rhythm channel (hERG) seen in lab tests, that needs more study.
• Drug interactions. Berberine at 300 mg three times a day slowed three liver enzymes (CYP2D6, CYP2C9 and CYP3A4) that clear many drugs (Guo 2012). DHB becomes berberine in the body, so assume the same interactions. Higher blood levels could make them stronger. See our page on berberine and statins.
• Diabetes medication. Berberine lowers blood glucose. If you take glucose lowering drugs, talk to your doctor first.
• Pregnancy and breastfeeding. NCCIH says berberine should not be used during pregnancy or breastfeeding, or given to infants.

This page is general information, not medical advice.

Sources

1. Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM. Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: a randomized, controlled, crossover pilot trial. Nutrients. 2021;14(1):124. PMID 35010998

2. Chang C, Roh YS, Du M, et al. Differences in metabolite profiles of dihydroberberine and micellar berberine in Caco-2 cells and humans: a pilot study. Int J Mol Sci. 2024;25(11):5625. PMID 38891813

3. Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008;57(5):1414-1418. PMID 18285556

4. Feng R, Shou JW, Zhao ZX, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015;5:12155. PMID 26174047

5. Wang D, Tang Y. Dihydroberberine in metabolic disorders: bioavailability, molecular mechanisms, toxicology, and future perspectives. Food Chem Toxicol. 2026;216:116267. PMID 42398618

6. Liu D, Zhao H, Zhang Y, Hu J, Xu H. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Front Pharmacol. 2025;16:1572197. PMID 40740996

7. Lewis KD, Falk M. Toxicological assessment of dihydroberberine. Food Chem Toxicol. 2022;168:113301. PMID 35868606

8. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217. PMID 21870106

9. National Center for Complementary and Integrative Health. Diabetes and dietary supplements: what you need to know (berberine section). nccih.nih.gov